Xeris Biopharma (NASDAQ:XERS) Trading Down 8.7% – Time to Sell?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares traded down 8.7% during trading on Wednesday . The company traded as low as $7.72 and last traded at $7.7440. 1,647,458 shares were traded during trading, a decline of 10% from the average daily volume of 1,833,908 shares. The stock had previously closed at $8.48.

Analyst Ratings Changes

Several research analysts have recently weighed in on XERS shares. Wall Street Zen lowered Xeris Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, September 5th. Leerink Partners upped their target price on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday. Barclays raised their target price on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $12.80.

Xeris Biopharma Stock Up 0.7%

The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The stock’s 50-day moving average price is $8.42 and its 200-day moving average price is $7.02. The company has a market cap of $1.41 billion, a P/E ratio of -70.23 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Insider Transactions at Xeris Biopharma

In related news, insider Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider owned 1,691,126 shares of the company’s stock, valued at approximately $13,579,741.78. This trade represents a 5.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00. Following the sale, the insider owned 1,366,053 shares of the company’s stock, valued at $11,638,771.56. This trade represents a 1.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 224,998 shares of company stock valued at $1,847,219 over the last ninety days. 4.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new position in shares of Xeris Biopharma during the fourth quarter valued at about $25,000. KBC Group NV acquired a new stake in shares of Xeris Biopharma in the 1st quarter worth about $27,000. Allworth Financial LP acquired a new stake in shares of Xeris Biopharma in the 2nd quarter worth about $34,000. State of Wyoming bought a new position in Xeris Biopharma in the 2nd quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd lifted its position in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.